-+ 0.00%
-+ 0.00%
-+ 0.00%

Shengda Biotech announced that Xinyinxiang, a wholly-owned subsidiary of the company, plans to acquire 25% of the total shares held by minority shareholders of the holding subsidiary Tongliao Shengda, with a transaction price of 120 million yuan. After deducting compensation payments related to the previous acquisition, it will actually have to pay 118 million yuan. The funding source is its own capital. After the transaction is completed, the company and its subsidiary Xinyinxiang will collectively hold 100% of Tongliao Shengda's shares. This transaction does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for review. Price payments and commercial and commercial changes have not yet been completed.

Zhitongcaijing·11/17/2026 08:49:03
Listen to the news
Shengda Biotech announced that Xinyinxiang, a wholly-owned subsidiary of the company, plans to acquire 25% of the total shares held by minority shareholders of the holding subsidiary Tongliao Shengda, with a transaction price of 120 million yuan. After deducting compensation payments related to the previous acquisition, it will actually have to pay 118 million yuan. The funding source is its own capital. After the transaction is completed, the company and its subsidiary Xinyinxiang will collectively hold 100% of Tongliao Shengda's shares. This transaction does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for review. Price payments and commercial and commercial changes have not yet been completed.